Collaboration
The boutique cancer drug discovery company Sareum plc has signed up the systems biology specialist Physiomics plc in support of Sareum’s existing joint research programme with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT).
Oxford-based Physiomics will use its computer models of biological processes to simulate the effects of cancer drugs in living systems. The research programme will focus on finalising dosing schedules for a development-stage cancer drug in combination with a marketed chemotherapeutic.
Tim Mitchell, CEO of Sareum, said this will add extra value at the point the product is out licensed.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
